BioNTech (NASDAQ:BNTX) Reaches New 12-Month High at $23.86

BioNTech SE (NASDAQ:BNTX) shares hit a new 52-week high during trading on Friday . The stock traded as high as $23.86 and last traded at $23.50, with a volume of 18234 shares changing hands. The stock had previously closed at $22.49.

A number of analysts have recently commented on the company. Svb Leerink initiated coverage on BioNTech in a research report on Monday, November 4th. They issued an “outperform” rating for the company. Wolfe Research started coverage on BioNTech in a research report on Tuesday, November 5th. They set an “outperform” rating and a $21.00 target price on the stock. Bank of America started coverage on BioNTech in a research report on Monday, November 4th. They set a “buy” rating and a $21.00 target price on the stock. Canaccord Genuity initiated coverage on shares of BioNTech in a research note on Monday, November 4th. They issued a “buy” rating and a $22.00 price target on the stock. Finally, Berenberg Bank began coverage on shares of BioNTech in a report on Monday, November 4th. They issued a “buy” rating and a $25.00 price target for the company. Eight investment analysts have rated the stock with a buy rating, The stock currently has an average rating of “Buy” and a consensus target price of $22.17.

The firm has a 50-day moving average price of $18.89.

BioNTech (NASDAQ:BNTX) last posted its quarterly earnings data on Thursday, November 14th. The company reported ($0.16) earnings per share (EPS) for the quarter, topping the Thomson Reuters’ consensus estimate of ($0.21) by $0.05. The firm had revenue of $31.87 million during the quarter, compared to analyst estimates of $28.83 million. On average, research analysts anticipate that BioNTech SE will post -0.79 earnings per share for the current year.

About BioNTech (NASDAQ:BNTX)

BioNTech SE, a biotechnology company, develops and commercializes immunotherapies for cancer and other diseases. The company is involved in developing FixVac product candidates, including BNT111, which is in Phase I clinical trial for advance melanoma; BNT112 for prostate cancer; BNT113 that is in Phase I clinical trial to treat HPV+ head and neck cancers; BNT114, which is in Phase I clinical trial for triple negative breast cancer; and BNT115 and BNT116 to treat other cancers, including ovarian cancer.

Featured Article: How accurate is the Rule of 72?

Receive News & Ratings for BioNTech Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for BioNTech and related companies with MarketBeat.com's FREE daily email newsletter.